NASHUA, N.H.--(BUSINESS WIRE)--iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced it has submitted data to the U.S. Food and Drug Administration (FDA) seeking 510(k) clearance of its VeraLook™ computer-aided detection (CAD) technology for CT colonography (CTC), or “virtual” colonoscopy. CTC employs cutting-edge, advanced visualization technology to produce three-dimensional images that permit a thorough and minimally invasive evaluation of the entire colorectal structure. iCAD’s VeraLook product uses advanced algorithms to detect and highlight potential polyps warranting closer review by a radiologist.
